| 1. | Progress of research of the mechanism of tamoxifen resistance in breast cancer
乳腺癌三苯氧胺耐药机制的研究进展 |
| 2. | Treatment of hyperplasia of mammary gland with guizhi fuling capsule and tamoxif
桂枝茯苓胶囊加三苯氧胺治疗乳腺增生症76例 |
| 3. | However , tamoxifen is associated with increased risk of death from other causes , such as strokes and endometrial cancer
但是三苯氧胺可以增加其他原因的死亡率，例如休克和子宫内膜癌等。 |
| 4. | Tamoxifen was the first estrogen modulator shown to increase survival and reduce the risk of breast cancer recurrence
三苯氧胺是第一个雌激素调节剂，可增加患者的生存率和降低乳腺癌复发的危险。 |
| 5. | Despite this risk , tamoxifen and another drug in this class , raloxifene , remain an extensively used and popular treatment
虽然存在这些副作用，三苯氧胺和另一种同类药物雷洛西芬已经被广泛用于乳腺癌的治疗。 |
| 6. | The observation of the curative effect of 46 cases of nausea and vomit after chemotherapy treated by combination of chinese traditional and western medicine
桂枝茯苓胶囊与三苯氧胺联合治疗乳腺增生病258例临床观察 |
| 7. | Of those , 96 were prescribed tamoxifen , a drug therapy considered one of the best options for blocking the hormones that promote cancerous cell growth
其中, 96名患者正在服用三苯氧胺，这种药物治疗被认为是阻断促进癌细胞生长的激素的最佳方案之一。 |
| 8. | The risk was highest for local and regional recurrence . these results held regardless of tamoxifen treatment , suggesting that adjuant radiation treatment was highly effectie
局限性复发的风险是最高的。不考虑三苯氧胺治疗，已有的结果表明辅助放疗是非常有效的。 |
| 9. | Recent evidence shows aromatase inhibitors used alone or in follow - up after two years of tamoxifen therapy demonstrates clear and , in some cases , improved reduction of recurrence risk
近年来证据显示芳香酶抑制剂单独或在三苯氧胺使用两年后来进行治疗乳腺癌可以促进降低复发率。 |
| 10. | Now , tamoxifen is still the standard endocrine therapeutic drug or the premenopausal patients , but aromatase inhibitors can bring more benefit for the postmenopausal patients
目前，三苯氧胺对绝经前患者仍是内分泌治疗的标准用药，但对绝经后患者应用芳香化酶抑制剂会有更大的效益。 |
